Carolyn F. Deacon

Carolyn F. Deacon

Associate Professor


  1. 2001
  2. Published

    Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. / Meier, J.J.; Huking, K.; Holst, J.J.; Deacon, C.F.; Schmiegel, W.H.; Nauck, M.A.

    In: Diabetes, No. 50, 2001, p. 2497-2504.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. 2000
  4. Published

    Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. / Deacon, C.F.; Nauck, M.A.; Meier, J.; Hücking, K.; Holst, J.J.

    In: Journal of Clinical Endocrinology and Metabolism, No. 85, 2000, p. 3575-3581.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    In vivo and in vitro degradation of glucagon-like peptide-2 in humans. / Hartmann, Bolette; Harr, M.B.; Jeppesen, P.B.; Wojdemann, M.; Deacon, C.F.; Mortensen, P.B.; Holst, J.J.

    In: Journal of Clinical Endocrinology and Metabolism, No. 85, 2000, p. 2884-2888.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. 1999
  7. Published

    Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. / Hansen, L; Deacon, C F; Orskov, C; Holst, J J.

    In: Molecular Endocrinology, Vol. 140, No. 11, 11.1999, p. 5356-63.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    Glucagon-like peptide-1 : a basis for new approaches to the management of diabetes. / Deacon, C F; Holst, Jens Juul; Carr, R D.

    In: Drugs of Today, Vol. 35, No. 3, 03.1999, p. 159-70.

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    Glucagon-like peptide-1(7-36)amide is transformed to glucagon-like peptide-1 (9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the intestinal L-cells. / Hansen, L.; Deacon, C.F.; Ørskov, C.; Holst, J.J.

    In: Endokrinologiya, No. 140, 1999, p. 5356-5363.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    Glucagon-like peptide-1: A basis for new approaches to the management of Diabetes. / Deacon, C.F.; Holst, J.J.; Carr, R.D.

    In: Drugs of Today, No. 35, 1999, p. 159-170.

    Research output: Contribution to journalJournal articleResearchpeer-review

  11. 1998
  12. Published

    Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. / Deacon, C.F.; Hughes, T.E.; Holst, J.J.

    In: Diabetes, No. 47, 1998, p. 764-769.

    Research output: Contribution to journalJournal articleResearchpeer-review

  13. Published

    Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. / Deacon, C.F.; Knudsen, L.B.; Madsen, K.; Wiberg, F.C.; Jacobsen, O.; Holst, J.J.

    In: Diabetologia, No. 41, 1998, p. 271-278.

    Research output: Contribution to journalJournal articleResearchpeer-review

  14. Published

    Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. / Holst, J.J.; Deacon, C.F.

    In: Diabetes, No. 47, 1998, p. 1663-1670.

    Research output: Contribution to journalJournal articleResearchpeer-review

ID: 9220